Metformin's primary safety concern in patients with impaired renal function is its ability to cause lactic acidosis.
Read More »Diabetes and COVID-19: Impact 18 Months into the Pandemic
Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.
Read More »Mortality and Cardiovascular Benefits of SGLT-2 Inhibitors in Type 2 Diabetes
Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?
Read More »Socioeconomic Status and Obesity in Patients with Diabetes
Are socioeconomic factors and obesity independently related to diabetes prevalence?
Read More »Hispanic/Latino Ethnicity Associated with Diabetes, Cognitive Decline, & Impairment
Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.
Read More »An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.
Read More »182% Increase of New-Onset T2D in Youth During the COVID-19 Pandemic
Worse clinical outcomes are seen during the pandemic for non-Hispanic Black youth with T2D.
Read More »The Rationale Behind Glycemic Worsening in Children and Adults
Are there predictors of glycemic worsening among patients recently diagnosed with type 2 diabetes?
Read More »An Under-Studied Population: Lean Patients with Diabetes?
Patients with normal BMI's and the indication of type 2 diabetes.
Read More »Faster Aspart vs. Insulin Aspart in Combo with Degludec
Faster aspart has a quicker onset of action, but does this impact glycemic control?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.